open label, single arm Phase 1/2 study for the treatment of sever localized scleroderma .

Trial Profile

open label, single arm Phase 1/2 study for the treatment of sever localized scleroderma .

Planning
Phase of Trial: Phase I/II

Latest Information Update: 18 Apr 2018

At a glance

  • Drugs FCX-013 (Primary)
  • Indications Scleroderma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 18 Apr 2018 According to Fibrocell media release, company expects to begin enrolment in this trial in the third quarter of 2018.
    • 12 Mar 2018 New trial record
    • 06 Mar 2018 According to Fibrocell media release, U.S. Food and Drug Administration (FDA) has granted allowance of its Investigational New Drug (IND) Application for FCX-013 to begin clinical trials for the treatment of moderate to severe localized scleroderma.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top